ClinicalTrials.gg
CompletedNCT06194214Updated Feb 21, 2025Results posted

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

A Phase 1 interventional study of Pirtobrutinib and Digoxin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Mar 2021, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting the blood tests to measure how much digoxin is in the bloodstream and how the body handles and eliminates it in healthy participants. The study will also evaluate the safety and tolerability of Pirtobrutinib. Participants will stay in this study for up to 58 days, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
  • Male and female participants in good health, determined by no findings from medical history, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator
  • Female participants of non- and male participants who follow standard methods
  • Must have comply with all study procedures, including the 20-night stay at the Clinical Research Unit (CRU) and follow-up phone call

Exclusion criteria

Exclusion Criteria:

  • History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Positive serologic test for surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, virus (HCV) antibody, or (HIV) antibody at Screening
  • Positive polymerase chain reaction (PCR) test for COVID-19 at Screening or Check-in (Day -1)
  • Known ongoing alcohol and/or drug abuse within 2 years prior to Screening
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)
  • Have previously completed or withdrawn from any other study investigating Pirtobrutinib (LOXO-305) and have previously received the product
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Digoxin + Pirtobrutinib

    Participants received oral dose of * 0.25 mg digoxin twice daily (BID) on Day 1 * 0.25 mg digoxin once daily (QD) from Day 2 to Day 7 * 200 mg Pirtobrutinib in combination with 0.25 mg digoxin QD starting from Day 8 to Day 16

    Drug: Pirtobrutinib · Drug: Digoxin

Interventions

  • Administered Orally.

    Also known as: LOXO-305, LY3527727

  • Administered Orally.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of Digoxin in Plasma

    PK: AUC\[0-t\] of Digoxin was reported.

    Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  2. PK: Area Under the Concentration During a Dosing Interval (AUC [Tau]) of Digoxin in Plasma

    PK: AUC \[tau\] of Digoxin was reported.

    Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  3. PK: Apparent Systemic Clearance (CL/F) of Digoxin in Plasma

    PK: CL/F of Digoxin in plasma was reported.

    Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  4. PK: Maximum Observed Plasma Concentration (Cmax) of Digoxin in Plasma

    PK: Cmax of Digoxin was reported.

    Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  5. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Digoxin in Plasma

    PK: Tmax of Digoxin was reported.

    Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  6. PK: Mean Residence Time (MRT) of Digoxin in Plasma

    PK: MRT of Digoxin was reported.

    Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  7. PK: Cumulative Amount of Drug Excreted Unchanged in Urine (Ae) of Digoxin

    PK: Ae of Digoxin in urine was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.

    Time frame: Day 7 and Day 16: Predose, 6, 12, 24 hours post dose

  8. PK: Fraction of Digoxin Excreted Unchanged in Urine (Fe) Expressed as Percentage of Dose Excreted

    PK: Fe of Digoxin was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.

    Time frame: Day 7 and Day 16: Predose, 6, 12, 24 hours post dose

  9. PK: Renal Clearance (CLr) of Digoxin in Plasma

    PK: CLr of Digoxin in plasma was reported.

    Time frame: Day 7: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  10. PK: Area Under the Concentration From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib in Plasma

    PK: AUC\[0-t\] of Pirtobrutinib was reported.

    Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  11. PK: Area Under the Concentration During a Dosing Interval (AUCtau) of Pirtobrutinib in Plasma

    PK: AUCtau of Pirtobrutinib was reported.

    Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  12. PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib in Plasma

    PK: CL/F of Pirtobrutinib in plasma was reported.

    Time frame: Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  13. PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib in Plasma

    PK: Cmax of Pirtobrutinib was reported.

    Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  14. PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib in Plasma

    PK: Tmax of Pirtobrutinib was reported.

    Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

  15. PK: Mean Residence Time (MRT) of Pirtobrutinib in Plasma

    PK: MRT of Pirtobrutinib was reported.

    Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose

07

Results

Posted Feb 21, 2025

Participant flow

Participant flow — Overall Study
MilestoneDigoxin + Pirtobrutinib
Started16
Received at least 1 dose of study drug16
Completed15
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of Digoxin in Plasma

PK: AUC\[0-t\] of Digoxin was reported.

Time frame:
Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of Digoxin in Plasma
hour*nanogram per milliliter (h*ng/mL)Digoxin + Pirtobrutinib
Day 714.6 ± 21.1
Day 817.1 ± 19.6
Day 1648.9 ± 22.0
PrimaryPK: Area Under the Concentration During a Dosing Interval (AUC [Tau]) of Digoxin in Plasma

PK: AUC \[tau\] of Digoxin was reported.

Time frame:
Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration During a Dosing Interval (AUC [Tau]) of Digoxin in Plasma
h*ng/mLDigoxin + Pirtobrutinib
Day 714.7 ± 21.1
Day 817.2 ± 19.6
Day 1620.4 ± 23.4
PrimaryPK: Apparent Systemic Clearance (CL/F) of Digoxin in Plasma

PK: CL/F of Digoxin in plasma was reported.

Time frame:
Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · liter per hour(L/h)
PK: Apparent Systemic Clearance (CL/F) of Digoxin in Plasma
liter per hour(L/h)Digoxin + Pirtobrutinib
Day 717.0 ± 21.1
Day 814.5 ± 19.6
Day 1612.2 ± 23.4
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of Digoxin in Plasma

PK: Cmax of Digoxin was reported.

Time frame:
Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Maximum Observed Plasma Concentration (Cmax) of Digoxin in Plasma
nanogram per milliliter (ng/mL)Digoxin + Pirtobrutinib
Day 71.57 ± 26.1
Day 82.38 ± 27.7
Day 162.45 ± 42.0
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Digoxin in Plasma

PK: Tmax of Digoxin was reported.

Time frame:
Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Median · hour
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Digoxin in Plasma
hourDigoxin + Pirtobrutinib
Day 71.27 (0.750 to 3.00)
Day 81.25 (0.750 to 3.00)
Day 161.00 (0.750 to 2.50)
PrimaryPK: Mean Residence Time (MRT) of Digoxin in Plasma

PK: MRT of Digoxin was reported.

Time frame:
Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · hours
PK: Mean Residence Time (MRT) of Digoxin in Plasma
hoursDigoxin + Pirtobrutinib
Day 752.2 ± 49.1
Day 865.2 ± 47.2
Day 1660.4 ± 52.5
PrimaryPK: Cumulative Amount of Drug Excreted Unchanged in Urine (Ae) of Digoxin

PK: Ae of Digoxin in urine was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.

Time frame:
Day 7 and Day 16: Predose, 6, 12, 24 hours post dose
Reported as:
Geometric mean · mg
PK: Cumulative Amount of Drug Excreted Unchanged in Urine (Ae) of Digoxin
mgDigoxin + Pirtobrutinib
Day 70.123 ± 23.3
Day 160.148 ± 18.2
PrimaryPK: Fraction of Digoxin Excreted Unchanged in Urine (Fe) Expressed as Percentage of Dose Excreted

PK: Fe of Digoxin was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.

Time frame:
Day 7 and Day 16: Predose, 6, 12, 24 hours post dose
Reported as:
Geometric mean · percentage of dose excreted in urine
PK: Fraction of Digoxin Excreted Unchanged in Urine (Fe) Expressed as Percentage of Dose Excreted
percentage of dose excreted in urineDigoxin + Pirtobrutinib
Day 749.2 ± 23.3
Day 1659.4 ± 18.2
PrimaryPK: Renal Clearance (CLr) of Digoxin in Plasma

PK: CLr of Digoxin in plasma was reported.

Time frame:
Day 7: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · L/h
PK: Renal Clearance (CLr) of Digoxin in Plasma
L/hDigoxin + Pirtobrutinib
Day 78.35 ± 15.0
Day 167.28 ± 17.0
PrimaryPK: Area Under the Concentration From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib in Plasma

PK: AUC\[0-t\] of Pirtobrutinib was reported.

Time frame:
Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib in Plasma
h*ng/mLDigoxin + Pirtobrutinib
Day 848400 ± 16.3
Day 16189000 ± 25.8
PrimaryPK: Area Under the Concentration During a Dosing Interval (AUCtau) of Pirtobrutinib in Plasma

PK: AUCtau of Pirtobrutinib was reported.

Time frame:
Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration During a Dosing Interval (AUCtau) of Pirtobrutinib in Plasma
h*ng/mLDigoxin + Pirtobrutinib
Day 848600 ± 16.3
Day 16106000 ± 21.0
PrimaryPK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib in Plasma

PK: CL/F of Pirtobrutinib in plasma was reported.

Time frame:
Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · L/h
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib in Plasma
L/hDigoxin + Pirtobrutinib
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib in Plasma1.89 ± 21.0
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib in Plasma

PK: Cmax of Pirtobrutinib was reported.

Time frame:
Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib in Plasma
ng/mLDigoxin + Pirtobrutinib
Day 84330 ± 17.1
Day 167530 ± 17.9
PrimaryPK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib in Plasma

PK: Tmax of Pirtobrutinib was reported.

Time frame:
Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Median · hours
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib in Plasma
hoursDigoxin + Pirtobrutinib
Day 82.50 (1.00 to 3.00)
Day 162.50 (0.500 to 4.00)
PrimaryPK: Mean Residence Time (MRT) of Pirtobrutinib in Plasma

PK: MRT of Pirtobrutinib was reported.

Time frame:
Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
Reported as:
Geometric mean · hours
PK: Mean Residence Time (MRT) of Pirtobrutinib in Plasma
hoursDigoxin + Pirtobrutinib
Day 822.6 ± 18.7
Day 1630.5 ± 17.5

Adverse events

Collected over Baseline up to Day 27. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.25 mg Digoxin0/16 (0%)0/16 (0%)5/16 (31.3%)
200 mg Pirtobrutinib + 0.25 mg Digoxin0/16 (0%)0/16 (0%)1/16 (6.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
Event0.25 mg Digoxin200 mg Pirtobrutinib + 0.25 mg Digoxin
Medical device site erythemaGeneral disorders2/160/16
Visual impairmentEye disorders0/161/16
Abdominal discomfortGastrointestinal disorders0/161/16
Abdominal distensionGastrointestinal disorders1/160/16
DiarrhoeaGastrointestinal disorders1/160/16
FlatulenceGastrointestinal disorders1/160/16
NauseaGastrointestinal disorders1/160/16
Medical device site injuryGeneral disorders1/160/16
Medical device site pruritusGeneral disorders1/160/16
Vascular access site haematomaInjury, poisoning and procedural complications1/160/16

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Digoxin + Pirtobrutinib
Mean41.8 ± 8.25
Sex: Female, Male
Sex: Female, Male(Participants)Digoxin + Pirtobrutinib
Female2
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Digoxin + Pirtobrutinib
Hispanic or Latino4
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Digoxin + Pirtobrutinib
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Digoxin + Pirtobrutinib
United States16
08

Study locations

1 site
  • Covance Clinical Research Unit
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jun 2021, 2 months.

Results were first posted in Feb 2025, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Jan 8, 2024
StartActual
Mar 11, 2021
Primary completionActual
Jun 9, 2021
CompletionActual
Jun 9, 2021
Results first posted
Feb 21, 2025
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06194214
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Mar 11, 2021
Primary completion
Jun 9, 2021
Completion
Jun 9, 2021
Results posted
Feb 21, 2025
Last update
Feb 21, 2025

Study contacts

Renee Ward, MD, PhD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion